Tonix Pharmaceuticals

TNXPPhase 3

Tonix Pharmaceuticals is a patient-focused biotechnology company dedicated to developing impactful treatments for complex, chronic conditions that defy easy answers, including nociplastic pain, immunology/immuno-oncology, and infectious diseases. Its strategy leverages an integrated clinical development engine to advance a diverse pipeline, with key programs like TNX-102 SL for acute stress disorder expected to report Phase 2 topline data in the second half of 2026. The company's mission is to empower patients to live fully through scientific rigor and a deep respect for the patient experience, supported by a leadership team with significant industry expertise.

Market Cap

$201.1M

Focus

Small Molecules

TNXP · Stock Price

USD 15.00147185.00 (-99.99%)

Historical price data

AI Company Overview

Technology Platform

Tonix utilizes multiple tailored technology approaches, including a sublingual delivery system for CNS drugs, a live horsepox virus vaccine platform for biodefense, monoclonal antibody development for immunology, and intranasal potentiated formulations for rare diseases.

Pipeline Snapshot

37 drugs in pipeline, 12 in Phase 3

Drug	Indication	Stage
TNX-102 SL + Placebo SL Tablet	Fibromyalgia	Phase 3
TNX-102 SL + Placebo SL Tablets	PTSD	Phase 3
TNX-102 SL + Placebo SL Tablet	PTSD	Phase 3
TNX-102 SL Tablet 2.8 mg	Primary Fibromyalgia	Phase 3
TNX-102 SL	Primary Fibromyalgia	Phase 3

Funding History

Total raised: $105M

PIPE$50MUndisclosedDec 15, 2021

PIPE$25MUndisclosedJun 15, 2020

IPO$30MUndisclosedFeb 15, 2016

Opportunities

Tonix's primary growth opportunity lies in successfully advancing TNX-102 SL for multiple CNS indications, starting with Acute Stress Disorder, which could unlock a blockbuster market.

Its live virus vaccine platform (TNX-801) presents a strategic opportunity in the growing biodefense and pandemic preparedness sector.

Additionally, orphan drug designations for programs like TNX-2900 in Prader-Willi Syndrome offer potential for high-value, expedited development pathways and premium pricing.

Risk Factors

Key risks include clinical trial failures, particularly for the lead CNS candidate TNX-102 SL; dependence on equity markets for funding as a pre-revenue company; intense competition across all therapeutic areas; and regulatory uncertainties inherent in drug development.

The company's valuation is highly sensitive to binary clinical readouts.

Competitive Landscape

Tonix faces competition from large pharmaceutical companies and other biotechs in every therapeutic area. In CNS, it competes with developers of antidepressants and neuromodulators. In immunology, it faces established biologic therapies. For its smallpox/mpox vaccine, it competes with approved vaccines like JYNNEOS. Differentiation is sought through novel formulations (sublingual, intranasal), unique mechanisms, and its live virus platform technology.